FDA Plans to Ease Testing Requirements to Accelerate Biosimilar Drug Approvals

The U.S. Food and Drug Administration (FDA) has proposed new draft guidance aimed at simplifying testing requirements for biosimilar medicines, a move intended to accelerate approvals and reduce development costs. The guidance recommends streamlining certain pharmacokinetic studies and allowing developers to rely on clinical data from comparable products approved outside the United States in some cases. Regulators estimate the changes could cut biosimilar development costs by up to $20 million and help expand access to lower-cost alternatives to expensive biologic therapies.

Reducing Development Burden for Biosimilar Makers

Under the proposed guidance, the FDA suggests eliminating some redundant studies used to demonstrate that a biosimilar closely matches its reference biologic drug. The agency also plans to withdraw older guidance from 2015, reflecting updated regulatory thinking after reviewing numerous biosimilar applications over the past decade. These changes aim to simplify the regulatory pathway and shorten development timelines.

Strategy to Improve Access to Affordable Biologic Medicines

Biologic drugs account for a significant portion of healthcare spending despite representing a small share of prescriptions, making biosimilars an important tool for lowering treatment costs. By reducing regulatory complexity and development expenses, the FDA hopes to encourage more companies to enter the biosimilar market, increasing competition and improving patient access to treatments for conditions such as cancer and autoimmune diseases.